platoseedplatoseed
Discovering drugs that target the DNA regulome
We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.
Talus Bio is a biotechnology company focused on unlocking and targeting the regulome to enable drug discovery. Their platform measures and modulates the regulome in native contexts to design interventions at the root of cellular decision making, with AI-generated libraries and high-throughput data to identify and advance drug targets.
Talus offers a proprietary platform that measures the regulome and enables design of interventions at regulatory targets. It combines: 1) Compounds and AI-designed chemical libraries aimed at modulating transcription factors and regulatory proteins; 2) Regulome-targeted assays that quantify targets in live cells with functional proteomics; 3) High-throughput cell-based assays generating tens of millions of compound-target interactions per month; 4) AI foundation models trained on functional and binding data across cell types, enabling discovery and optimization. The pipeline includes targets across transcription factors, cofactors, and splicing regulators, with programs spanning oncology, rare disease, and immune dysfunction, and partnerships to discover molecules, identify targets/biomarkers, deconvolve mechanisms, predict toxicity, and progress pipeline programs toward clinical development.
Who it’s for: Biotech and pharmaceutical companies pursuing target discovery and drug development in oncology, immunology, cardiometabolic diseases, and rare diseases; academic or industry teams exploring regulome biology and regulatory targets.
Hiring/pipeline activity and partnerships mentioned
I'm the co-founder of Talus Bio. Prior to Talus, I trained with Jay Bradner at Harvard in medicinal chemistry, drug screening, and drug development for gene regulators. After that, I moved to Seattle to continue my training in epigenomics and proteomics, and these were all combined to develop the Talus gene regulator platform.
I'm Talus Bio's CTO, where my focus is on developing techniques for quantitative proteomics and in particular the challenges associated with scaling-up quantitative proteomics experiments. I’ve trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania.
Using the immune system to cure disease
Unleashing the potential of DNA and RNA based therapies using AI
